Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

European Journal of Cancer

Volumn 49, Issue 17, 2013, Pages 3666-3670

  Ghez, David ^a   Micol, Jean Baptiste ^a   Pasquier, Florence ^a   Auger, Nathalie ^a   Saada, Véronique ^a   Spentchian, Marc ^b   Ianotto, Jean Christophe ^c   Bourhis, Jean Henri ^a   Bennaceur Griscelli, Anelyse ^a   Terré, Christine ^b   Castaigne, Sylvie ^b   Rigaudeau, Sophie ^b   Rousselot, Philippe ^b   De Botton, Stéphane ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c CHU MORVAN   (France)

Author keywords

Blast phase; Chronic myelogenous leukaemia; Tyrosine kinase inhibitors

Indexed keywords

AZACITIDINE; BCR ABL PROTEIN; DASATINIB; NILOTINIB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASTHENIA; BLAST CELL CRISIS; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

BLAST PHASE; CHRONIC MYELOGENOUS LEUKAEMIA; TYROSINE KINASE INHIBITORS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BLAST CRISIS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84886796489     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.147     Document Type: Article

References (20)

1. H.M. Kantarjian, J. Shan, and T. Smith Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase Cancer 92 10 2001 2501 2507
2. S. Sacchi, H.M. Kantarjian, and S. O'Brien Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients Cancer 86 12 1999 2632 2641
3. A. Gratwohl, J. Hermans, and D. Niederwieser Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic leukemia working party of the european group for bone marrow transplantation Bone Marrow Transplant 12 5 1993 509 516
4. J. Cortes, D.W. Kim, and E. Raffoux Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Leukemia 22 12 2008 2176 2183
5. H.M. Kantarjian, J. Cortes, and S. O'Brien Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase Blood 99 10 2002 3547 3553
6. F. Palandri, F. Castagnetti, and N. Testoni Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up Haematologica 93 12 2008 1792 1796
7. C.L. Sawyers, A. Hochhaus, and E. Feldman Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 10 2002 3530 3539
8. A. Sureda, and M. Carrasco De MM, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia Haematologica 88 11 2003 1213 1220
9. G. Saglio, A. Hochhaus, and Y.T. Goh Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily Cancer 116 16 2010 Aug 15 3852 3861
10. B. Deau, F.E. Nicolini, and J. Guilhot The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study) Leuk Res 35 6 2011 777 782
11. S. Fruehauf, J. Topaly, and E.C. Buss Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis Cancer 109 8 2007 1543 1549
12. A. Quintas-Cardama, H. Kantarjian, and G. Garcia-Manero A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase Leuk Lymphoma 48 2 2007 283 289
13. H.M. Kantarjian, S.M. O'Brien, and M. Keating Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia Leukemia 11 10 1997 1617 1620
14. H.M. Kantarjian, S. O'Brien, and J. Cortes Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 3 2003 522 528
15. Y. Oki, H.M. Kantarjian, and V. Gharibyan Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 109 5 2007 899 906
16. J.J. Janssen, F. Denkers, P. Valk, J.J. Cornelissen, G.J. Schuurhuis, and G.J. Ossenkoppele Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells Haematologica 95 6 2010 1036 1037
17. J. Jelinek, V. Gharibyan, and M.R. Estecio Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia PLoS One 6 7 2011 e22110
18. E. Uehara, S. Takeuchi, and Y. Yang Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis Oncol Lett 3 1 2012 Jan 190 192
19. L. Li, L. Wang, and L. Li Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib Cancer Cell 21 2 2012 266 281
20. B. Zhang, A.C. Strauss, and S. Chu Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate Cancer Cell 17 5 2010 427 442